Next Article in Journal
Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the Use of Silymarin
Previous Article in Journal
The Potential Application of Allium Extracts in the Treatment of Gastrointestinal Cancers
Article

Interest in Immunosuppression Withdrawal among Liver Transplant and Autoimmune Hepatitis Patients

Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Paolo Muratori
Gastroenterol. Insights 2021, 12(2), 147-154; https://0-doi-org.brum.beds.ac.uk/10.3390/gastroent12020013
Received: 2 March 2021 / Revised: 23 March 2021 / Accepted: 29 March 2021 / Published: 1 April 2021
(This article belongs to the Section Liver)
Immunosuppression withdrawal (ISW) is considered in liver transplant recipients (LTRs) and autoimmune hepatitis patients (AIHPs). Immunosuppressive therapy (IST) can be burdensome both financially and due to its side effect profile, making ISW an important intervention to consider. Data on patient interest in ISW would be helpful to providers in ISW decision-making. We conducted independent single-center surveys of LTR and AIHP attitudes on IST and withdrawal interest. Of 325 LTRs screened, 120 completed the survey (50% female, mean age 58 ± 14 years, mean time since transplant 8 ± 10.5 years and 79.5% Caucasian). Of 100 AIHPs screened, 45 completed the survey (77.8% female, mean age 54 ± 2 and 82.2% Caucasian). A higher percentage of AIHPs expressed concern with their IST and were interested in ISW compared with LTRs. However, over a third of LTRs were interested in ISW, particularly those with knowledge of this potential intervention. LTRs who discussed ISW with a physician were more likely to desire withdrawal (p = 0.02; OR = 2.781 (95% CI = 1.125, 6.872)). As patient interest in ISW is of growing interest, investigators should continue to assess patient-reported desires and outcomes and pursue strategies to achieve immunological tolerance. View Full-Text
Keywords: hepatitis; autoimmune; liver transplantation; immunosuppression; patient-reported outcome measures; decision-making hepatitis; autoimmune; liver transplantation; immunosuppression; patient-reported outcome measures; decision-making
Show Figures

Figure 1

MDPI and ACS Style

Sharabi, E.; Carroll, A.; Cummings, P.; Levitsky, J. Interest in Immunosuppression Withdrawal among Liver Transplant and Autoimmune Hepatitis Patients. Gastroenterol. Insights 2021, 12, 147-154. https://0-doi-org.brum.beds.ac.uk/10.3390/gastroent12020013

AMA Style

Sharabi E, Carroll A, Cummings P, Levitsky J. Interest in Immunosuppression Withdrawal among Liver Transplant and Autoimmune Hepatitis Patients. Gastroenterology Insights. 2021; 12(2):147-154. https://0-doi-org.brum.beds.ac.uk/10.3390/gastroent12020013

Chicago/Turabian Style

Sharabi, Eden, Allison Carroll, Peter Cummings, and Josh Levitsky. 2021. "Interest in Immunosuppression Withdrawal among Liver Transplant and Autoimmune Hepatitis Patients" Gastroenterology Insights 12, no. 2: 147-154. https://0-doi-org.brum.beds.ac.uk/10.3390/gastroent12020013

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop